[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志,2021,7(2): 1-13.
[3] Owen KL, Brockwell K, Parker BS.JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression[J]. Cancers (Basel), 2019, 11(12):2002.
[4] Taheri M, Oskooei VK, Ghafouri-Fard S.Protein inhibitor of activated STAT genes are differentially expressed in breast tumor tissues[J]. Per Med, 2019, 16(4): 277-285.
[5] Lai Z, Adzigbli L, Chen Q, et al.Identification and Allelic Variants Associated With Cold Tolerance of PmPIAS in Pinctada fucata martensii[J]. Front Physiol, 2021, 12: 634838.
[6] Wang L, Banerjee S.Differential PIAS3 expression in human malignancy[J]. Oncol Rep, 2004, 11(6): 1319-1324.
[7] Brantley EC, Nabors LB, Gillespie GY, et al.Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression[J]. Clin Cancer Res, 2008, 14(15): 4694-4704.
[8] Tirard M, Jasbinsek J, Almeida OF, et al.The manifold actions of the protein inhibitor of activated STAT proteins on the transcriptional activity of mineralocorticoid and glucocorticoid receptors in neural cells[J]. J Mol Endocrinol, 2004, 32(3): 825-841.
[9] Lussier-price M, Mascle XH, Cappadocia L, et al. Characterization of a C-Terminal SUMO-Interacting Motif Present in Select PIAS-Family Proteins[J]. Structure, 2020, 28(5): 573-585.e5.
[10] Jiménez-lara AM, Heine MJ, Gronemeyer H. PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2[J]. FEBS Lett, 2002, 526(1-3): 142-146.
[11] Rabellino A, Andreani C, Scaglioni PP.The Role of PIAS SUMO E3-Ligases in Cancer[J]. Cancer Res, 2017, 77(7): 1542-1547.
[12] Duval D, Duval G, Kedinger C, et al.The 'PINIT' motif, of a newly identified conserved domain of the PIAS protein family, is essential for nuclear retention of PIAS3L[J]. FEBS Lett, 2003, 554(1-2): 111-118.
[13] Zhao Y, He J, Li Y, et al.NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR[J]. Signal Transduct Target Ther, 2020, 5(1): 44.
[14] Chen Z, Zhang Y, Guan Q, et al.Linking nuclear matrix-localized PIAS1 to chromatin SUMOylation via direct binding of histones H3 and H2A.Z[J]. J Biol Chem, 2021, 297(4): 101200.
[15] Sharma A, Khan H, Singh TG, et al.Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling[J]. Int J Mol Sci, 2021, 22(21):11971.
[16] Hung PF, Hong TM, Chang CC, et al.Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis[J]. J Exp Clin Cancer Res, 2019, 38(1): 5.
[17] Chandhoke AS, Chanda A, Karve K, et al.The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness[J]. Oncotarget, 2017, 8(13): 21001-21014.
[18] Kukkula A, Ojala VK, Mendez LM, et al.Therapeutic Potential of Targeting the SUMO Pathway in Cancer[J]. Cancers (Basel), 2021, 13(17): 4402.
[19] Heppler LN, Frank DA.Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors[J]. Trends Cancer, 2017, 3(12): 816-827.
[20] Rah B, Rather RA, Bhat GR, et al.JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies[J]. Front Pharmacol, 2022, 13: 821344.
[21] Niu GJ, Xu D, Yuan WJ, et al.Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation[J]. Front Immunol, 2018, 9: 2392.
[22] Wang HQ, Man QW, Huo FY, et al.STAT3 pathway in cancers: Past, present, and future[J]. MedComm (2020), 2022, 3(2): e124.
[23] Bakhmet EI, Tomilin AN.Key features of the POU transcription factor Oct4 from an evolutionary perspective[J]. Cell Mol Life Sci, 2021, 78(23): 7339-7353.
[24] Tolkunova E, Malashicheva A, Parfenov VN, et al.PIAS proteins as repressors of Oct4 function[J]. J Mol Biol, 2007, 374(5): 1200-1212.
[25] Abdelaziz LA, Ebian HF, Harb OA, et al.Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients[J]. Contemp Oncol(Pozn), 2022, 26(1): 78-87.
[26] Najafzadeh B, Asadzadeh Z, Motafakker Azad R, et al.The oncogenic potential of NANOG: An important cancer induction mediator[J]. J Cell Physiol, 2021, 236(4): 2443-2458.
[27] Biondini M, Kiepas A, El-houjeiri L, et al. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin[J]. Oncogene, 2022, 41(12): 1701-1717.
[28] Levy C, Sonnenblick A, Razin E.Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3[J]. Mol Cell Biol, 2003, 23(24): 9073-9080.
[29] Fabi F, Asselin E.Expression, activation, and role of AKT isoforms in the uterus[J]. Reproduction, 2014, 148(5): R85-95.
[30] Ghafouri-Fard S, Khanbabapour Sasi A, Hussen BM, et al.Interplay between PI3K/AKT pathway and heart disorders[J]. Mol Biol Rep, 2022,49(10):9767-9781.
[31] Ogata Y, Osaki T, Naka T, et al.Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation[J]. Neoplasia, 2006, 8(10): 817-825.
[32] Jiang W, Rixiati Y, Huang H, et al.Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway[J]. Cancer Med, 2020, 9(21): 8173-8185.
[33] Hua Y, Camarco DP, Strock CJ, et al.High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions[J]. Methods Mol Biol, 2018, 1683: 211-227.
[34] Sundvall M, Korhonen A, Vaparanta K, et al.Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein[J]. J Biol Chem, 2012, 287(27): 23216-23226.
[35] 蒋蒙蒙. miR-9/miR-181a为核心的ceRNA网络在IL-6/STAT3信号通路促进乳腺癌eMDSCs生成和免疫抑制活性中的调控研究[D]. 天津:天津医科大学,2019.
[36] Agboola A, Musa A, Banjo A, et al.PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women[J]. J Clin Pathol, 2014, 67(4): 301-306. |
